{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:31:01Z","timestamp":1707525061729},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,28]]},"DOI":"10.7759\/cureus.41074","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T11:44:57Z","timestamp":1687952697000},"source":"Crossref","is-referenced-by-count":0,"title":["Adenocarcinoma of an Unknown Primary Site: Presentation, Diagnosis, and Management"],"prefix":"10.7759","author":[{"given":"Jaafar","family":"Abou-Ghaida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adya A","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheela","family":"Anasseri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tye","family":"Barber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Carcinoma of unknown primary","author":"Raghav K","year":"2022","unstructured":"Raghav K, Abbruzzese JL, Varadhachary GR. Carcinoma of unknown primary. Harrison's Principles of Internal Medicine, 21e. Loscalzo J, Fauci A, Kasper D, Hauser S, Longo D, Jameson J (ed): McGraw Hill, New York; 2022."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2014.0481","article-title":"Patients with cancer of unknown primary: a retrospective analysis of 223 patients with adenocarcinoma or undifferentiated carcinoma","volume":"111","author":"L\u00f6ffler H","year":"2014","unstructured":"L\u00f6ffler H, Puthenparambil J, Hielscher T, Neben K, Kr\u00e4mer A. Patients with cancer of unknown primary: a retrospective analysis of 223 patients with adenocarcinoma or undifferentiated carcinoma. Dtsch Arztebl Int. 2014, 111:481-7. 10.3238\/arztebl.2014.0481","journal-title":"Dtsch Arztebl Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds357","article-title":"Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling","volume":"23","author":"Oien KA","year":"2012","unstructured":"Oien KA, Dennis JL. Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling. Ann Oncol. 2012, 23:271-7. 10.1093\/annonc\/mds357","journal-title":"Ann Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10035","article-title":"Molecular driver alterations and their clinical relevance in cancer of unknown primary site","volume":"7","author":"L\u00f6ffler H","year":"2016","unstructured":"L\u00f6ffler H, Pfarr N, Kriegsmann M, et al.. Molecular driver alterations and their clinical relevance in cancer of unknown primary site. Oncotarget. 2016, 7:44322-9. 10.18632\/oncotarget.10035","journal-title":"Oncotarget"},{"key":"ref5","article-title":"Adenocarcinoma of unknown primary site","author":"Hainsworth JD","year":"2023","unstructured":"Hainsworth JD, Greco FA . Adenocarcinoma of unknown primary site. UpToDate. Post TW (ed): UpToDate, Waltham, MA; 2023."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199307223290407","article-title":"Treatment of patients with cancer of an unknown primary site","volume":"329","author":"Hainsworth JD","year":"1993","unstructured":"Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. N Engl J Med. 1993, 329:257-63. 10.1056\/NEJM199307223290407","journal-title":"N Engl J Med"},{"key":"ref7","article-title":"Carcinoma of unknown primary origin","volume":"1","author":"Varadhachary GR","year":"2007","unstructured":"Varadhachary GR. Carcinoma of unknown primary origin. Gastrointest Cancer Res. 2007, 1:229-35.","journal-title":"Gastrointest Cancer Res"},{"key":"ref8","article-title":"Tumor markers in metastatic disease from cancer of unknown primary origin","volume":"8","author":"Milovi\u0107 M","year":"2002","unstructured":"Milovi\u0107 M, Popov I, Jeli\u0107 S. Tumor markers in metastatic disease from cancer of unknown primary origin. Med Sci Monit. 2002, 8:25-30.","journal-title":"Med Sci Monit"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4103\/0975-5950.196135","article-title":"Tumor markers: a diagnostic tool","volume":"7","author":"Nagpal M","year":"2016","unstructured":"Nagpal M, Singh S, Singh P, Chauhan P, Zaidi MA. Tumor markers: a diagnostic tool. Natl J Maxillofac Surg. 2016, 7:17-20. 10.4103\/0975-5950.196135","journal-title":"Natl J Maxillofac Surg"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.11.013","article-title":"Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Kr\u00e4mer A","year":"2023","unstructured":"Kr\u00e4mer A, Bochtler T, Pauli C, et al.. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023, 34:228-46. 10.1016\/j.annonc.2022.11.013","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv543","article-title":"Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance)","volume":"27","author":"Yoon HH","year":"2016","unstructured":"Yoon HH, Foster NR, Meyers JP, et al.. Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Ann Oncol. 2016, 27:339-44. 10.1093\/annonc\/mdv543","journal-title":"Ann Oncol"},{"key":"ref12","article-title":"Tools for genetics and genomics: gene expression profiling","author":"Steiling K","year":"2022","unstructured":"Steiling K, Christenson S. Tools for genetics and genomics: gene expression profiling. UpToDate. Post TW (ed): UpToDate, Waltham, MA; 2022."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-022-03435-z","article-title":"Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs)","volume":"482","author":"Pisacane A","year":"2023","unstructured":"Pisacane A, Cascardi E, Berrino E, et al.. Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs). Virchows Arch. 2023, 482:463-75. 10.1007\/s00428-022-03435-z","journal-title":"Virchows Arch"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13597","article-title":"Comprehensive genomic profiling of carcinoma of unknown primary origin: retrospective molecular classification considering the CUPISCO study design","volume":"26","author":"Ross JS","year":"2021","unstructured":"Ross JS, Sokol ES, Moch H, et al.. Comprehensive genomic profiling of carcinoma of unknown primary origin: retrospective molecular classification considering the CUPISCO study design. Oncologist. 2021, 26:e394-402. 10.1002\/onco.13597","journal-title":"Oncologist"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-015-0133-8","article-title":"Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay","volume":"19","author":"Greco FA","year":"2015","unstructured":"Greco FA, Lennington WJ, Spigel DR, Hainsworth JD. Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay. Mol Diagn Ther. 2015, 19:91-7. 10.1007\/s40291-015-0133-8","journal-title":"Mol Diagn Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4643","article-title":"Site-specific and targeted therapy based on molecular profiling by next-generation sequencing for cancer of unknown primary site: a nonrandomized Phase 2 clinical trial","volume":"6","author":"Hayashi H","year":"2020","unstructured":"Hayashi H, Takiguchi Y, Minami H, et al.. Site-specific and targeted therapy based on molecular profiling by next-generation sequencing for cancer of unknown primary site: a nonrandomized Phase 2 clinical trial. JAMA Oncol. 2020, 6:1931-8. 10.1001\/jamaoncol.2020.4643","journal-title":"JAMA Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/154208-adenocarcinoma-of-an-unknown-primary-site-presentation-diagnosis-and-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:00:33Z","timestamp":1707508833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/154208-adenocarcinoma-of-an-unknown-primary-site-presentation-diagnosis-and-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,28]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.41074","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,28]]}}}